Larvol Delta - Atsena-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-from-the-US-FDA-for-ATSN201-Gene-Therapy-to-Treat-Xlinked-Retinoschisis

ATSN-201 - Atsena Therap

https://www.globenewswire.com/news-release/2024/08/14/2929958/0/en/Atsena-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-from-the-U-S-FDA-for-ATSN-201-Gene-Therapy-to-Treat-X-linked-Retinoschisis.html

Aug 14, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next